Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Prothena Corporation PLC (NASDAQ:PRTA)

54.84
Delayed Data
As of Dec 08
 +1.65 / +3.10%
Today’s Change
28.20
Today|||52-Week Range
73.47
-19.48%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.8B

Company Description

Prothena Corp. Plc is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. It also focuses on therapeutic monoclonal antibodies directed specifically to disease causing proteins. The company's antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis, Parkinson's disease and other related synucleinopathies and novel cell adhesion targets involved in inflammatory diseases and cancers. Prothena was founded on December 20, 2012 and is headquartered in Dun Laoghaire, Ireland.

Contact Information

Prothena Corp. Plc
Adelphi Plaza
Dun Laoghaire Dublin 14
P:(531) 236-2500
Investor Relations:
(650) 837-8535

Employees

Shareholders

Individual stakeholders9.34%
Mutual fund holders84.46%
Other institutional25.60%

Top Executives

Gene G. KinneyPresident, Chief Executive Officer & Director
Tran B. NguyenChief Financial Officer & Head-Investor Relations
Martin KollerChief Medical Officer
Tara NickersonChief Business Officer
David B. McninchChief Commercial Officer